HCF
0.037
105.6%
SRN
0.001
-50%
MEU
0.13
83.1%
FBR
0.003
-40%
CTN
0.003
50%
SPX
0.002
-33.3%
CHM
0.004
33.3%
NES
0.006
-25%
ROG
0.004
33.3%
MIO
0.02
-23.1%
WHK
0.009
28.6%
A11
0.155
-20.5%
ALV
0.083
25.8%
CDE
0.008
-20%
STV
0.011
22.2%
MOH
0.008
-20%
BLU
0.006
20%
RLG
0.004
-20%
KKO
0.067
19.6%
SPQ
0.009
-18.2%
LKE
0.094
19%
NFL
0.115
-17.9%
TSK
0.13
18.2%
GRL
0.014
-17.6%
GLL
0.007
16.7%
TRU
0.014
-17.6%
HMX
0.028
16.7%
AYT
0.005
-16.7%
PLC
0.007
16.7%
VAR
0.005
-16.7%
RAD
0.021
16.7%
LMS
0.405
-16.5%
AXI
0.015
15.4%
FTI
0.185
-15.9%
FEX
0.5
14.9%
ACP
0.023
-14.8%
RNT
0.055
14.6%
RGL
0.006
-14.3%
HMI
0.04
14.3%
SMM
0.012
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747